**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 54433

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Genetic association analysis of *CLEC5A* and *CLEC7A* gene single-nucleotide polymorphisms and Crohn’s disease**

Elleisy N *et al*. Single-nucleotide polymorphisms and Crohn’s disease

Nagi Elleisy, Sarah Rohde, Astrid Huth, Nicole Gittel, Änne Glass, Steffen Möller, Georg Lamprecht, Holger Schäffler, Robert Jaster

**Nagi Elleisy, Sarah Rohde, Astrid Huth, Nicole Gittel, Georg Lamprecht, Holger Schäffler, Robert Jaster**, Department of Medicine II, Division of Gastroenterology, Rostock University Medical Center, Rostock 18057, Germany

**Änne Glass, Steffen Möller,** Institute for Biostatistics and Informatics in Medicine and Ageing Research, Rostock 18057, Germany

**Author contributions:** Schäffler H, Rohde S and Jaster R designed the study; Huth A, Schäffler H and Lamprecht G took reponsibility for patient care and follow-up; Elleisy N, Rohde S and Jaster R performed the experiments; Gittel N, Huth A and Schäffler H collected the samples and performed the clinical characterisation of the patients; Elleisy N, Glass Ä, Möller S and Jaster R performed the biostatistics; all authors analyzed the data; Schäffler H and Jaster R wrote the manuscript and contributed equally and share senior authorship.

**Supported by** the Damp-Foundation, No. 2016-04.

**Corresponding author: Robert Jaster, MD, Academic Research, Professor, Senior Postdoctoral Fellow, Senior Scientist,** Department of Medicine II, Division of Gastroenterology, Rostock University Medical Center, E.-Heydemann-Str. 6, Rostock 18057, Germany. robert.jaster@med.uni-rostock.de

**Received:** February 4, 2020

**Revised:** April 13, 2020

**Accepted:** April 29, 2020

**Published online:** May 14, 2020

**Abstract**

BACKGROUND

Crohn’s disease (CD) is characterized by a multifactorial etiology and a significant impact of genetic traits. While *NOD2* mutations represent well established risk factors of CD, the role of other genes is incompletely understood.

AIM

To challenge the hypothesis that single nucleotide polymorphisms (SNPs) in the genes *CLEC5A* and *CLEC7A*, two members of the C-type lectin domain family of pattern recognition receptors, may be associated with CD.

METHODS

SNPs in *CLEC5A*, *CLEC7A* and the known CD risk gene *NOD2* were studied using real time PCR-based SNP assays. Therefore, DNA samples from 175 patients and 157 healthy donors were employed. Genotyping data were correlated with clinical characteristics of the patients and the results of gene expression data analyses.

RESULTS

In accordance with previous studies, rs2066844 and rs2066847 in *NOD2* were found to be significantly associated with CD (allelic *P* values = 0.0368 and 0.0474, respectively). Intriguingly, for genotype AA of rs1285933 in *CLEC5A*, a potential association with CD (recessive *P* = 0.0523; odds ratio = 1.90) was observed. There were no associations between CD and SNPs rs2078178 and rs16910631 in *CLEC7A*. Variants of rs1285933 had no impact on *CLEC5A* gene expression. In contrast, genotype-dependent differences of *CXCL5* expression in peripheral blood mononuclear cells were observed. There is no statistical interaction between the tested SNPs of *NOD2* and *CLEC5A*, suggesting of a novel pathway contributing to the disease.

CONCLUSION

Our data encourage enlarged follow-up studies to further address an association of SNP rs1285933 in *CLEC5A* with CD. The C-type lectin domain family member also deserves attention regarding a potential role in the pathophysiology of CD.

**Key words:** Crohn’s disease; Single nucleotide polymorphisms; *NOD2*; *CLEC5A*; Gene expression; *CXCL5*

Elleisy N, Rohde S, Huth A, Gittel N, Glass Ä, Möller S, Lamprecht G, Schäffler H, Jaster R. Genetic association analysis of *CLEC5A* and *CLEC7A* gene single-nucleotide polymorphisms and Crohn’s disease. *World J Gastroenterol* 2020; 26(18): 2194-2202

URL: https://www.wjgnet.com/1007-9327/full/v26/i18/2194.htm

DOI: https://dx.doi.org/10.3748/wjg.v26.i18. 2194

**Core tip:** The genetic traits of Crohn’s disease (CD) are incompletely understood. Here, we report a potential association of single nucleotide polymorphism (SNP) rs1285933 in *CLEC5A,* a member of the C-type lectin domain family of pattern recognition receptors, with CD. Variants of SNP rs1285933 had no impact on *CLEC5A* gene expression in peripheral blood mononuclear cells but correlated with the expression of *CXCL5*. The SNPs rs2078178 and rs16910631 in *CLEC7A* were not associated with the disease. The role of *CLEC5A* in the pathophysiology of CD deserves further attention.

**INTRODUCTION**

Together with ulcerative colitis, Crohn’s disease (CD) represents the most common and clinically relevant inflammatory bowel disease[1,2]. While it is generally accepted that the pathogenesis of the disease is multifactorial and involves an inappropriate activation of the mucosal immune system, the precise contribution of individual environmental factors and genetic traits remains elusive[1-3]. Mutations in the *NOD2* gene represent the best-characterized genetic association of CD[4-6]. Nucleotide-binding oligomerization domain 2 (NOD2) belongs to the pattern recognition receptor (PRR) family and acts as an intracellular sensor for peptidoglycan[7,8] and its fragment muramyl dipeptide[9,10]. Downstream of NOD2, the transcription factor NF-κB plays a key role in the transduction of receptor-generated signals[11].

C-type lectin domain (CLEC) receptors comprise a large family of carbohydrate-binding proteins[12]. Various CLEC family receptors are considered to exert functions as PRR since they recognize pathogen-associated molecules and may induce intracellular signaling pathways that regulate inflammatory processes. CLEC proteins are crucially involved in the immune response to fungal pathogens, but have also been implicated in anti-bacterial, anti-viral and anti-parasitic defense mechanisms[13,14]. Despite their functional similarities to NOD2, CLEC proteins have not been systematically studied in the context of IBD yet. Interestingly, a single nucleotide polymorphism (SNP) in the *CLEC7A* (*DECTIN-1*) gene, rs2078178, has been reported to be strongly linked to a severe form of ulcerative colitis, and this association was even stronger for the two-marker haplotype rs2078178 to rs16910631[15]. For another *CLEC* gene, *CLEC5A*, we recently observed a CD-associated expression pattern with higher transcript levels in patient-derived peripheral blood mononuclear cells than in corresponding controls. Furthermore, *CLEC5A* showed a *NOD2*-dependent expression profile, supporting the hypothesis that both proteins may act in a regulatory network with a pathophysiological role in CD[16]. Given that defective bacterial clearance may contribute to the pathogenesis of CD[17,18], it is important to note that *CLEC5A* has also been suggested to be essentially involved in innate immunity through neutrophil trap formation and secretion of different proinflammatory cytokines after stimulation with *Listeria monocytogenes*[19]. Interestingly, the SNP rs1285933 in *CLEC5A* is associated with dengue severity[20], and *CLEC5A* has been shown to be critical for dengue-virus-induced lethal disease[21].

Here, we have addressed the question if the SNPs rs2078178 and rs16910631 in *CLEC7A* and rs1285933 in *CLEC5A* are associated with CD and have analyzed effects of rs1285933 at the level of gene expression. For comparison and a postive control, the known disease-associated SNPs rs2066844 (SNP8), rs2066845 (SNP12) and rs2066847 (SNP13)[5,6] in *NOD2* were included into the investigations as well.

**MATERIALS AND METHODS**

***Patients***

From October 2015 until June 2017, 175 patients (102 females and 73 males; mean age 43.1 ± 14.7 years) with CD from the Department of Gastroenterology of Rostock University Medical Center (Rostock, Germany) were included in the study. This cohort of CD patients represents an extension of a cohort that we have previously characterized regarding relationships between mutations in the *NOD2* gene, the disease phenotype and anti-tumor necrosis factor-α trough levels[22].

The diagnosis of CD was based on clinical, endoscopic, histological and radiological findings of the patients. The following clinical data were collected: Age, sex, age at diagnosis, duration of the disease, disease location, disease behavior, disease activity (assessed by the Crohn’s disease activity index[23] and the Harvey–Bradshaw index[24]), disease-specific medications, and previous history of surgery (*i.e*., colectomy). CD was stratified *via* the Montreal classification[25]. Unrelated and healthy subjects from Germany (*n* = 157; 101 females and 56 males; mean age 25.3 ± 5.7 years) served as controls. The study was approved by the Local Ethics Board of the University of Rostock (A-2017-0137). We obtained written informed consent from all participants prior to their enrollment.

***DNA extraction***

EDTA whole-blood samples were subjected to DNA extraction employing the QIAamp DNA blood mini kit according to the instructions of the manufacturer (Qiagen, Hilden, Germany).

***Genotyping***

Genotyping was performed using TaqMan™ SNP Genotyping Allelic Discrimination Assays with VIC- and FAM-labeled probes (Thermo Fisher Scientific, Karlsruhe, Germany) for rs1285933 (*CLEC5A*, Assay-ID: [C\_\_\_9506735\_10](https://www.thermofisher.com/order/genome-database/details/genotyping/C___9506735_10?CID=&ICID=&subtype=)), rs2078178 (*CLEC7A*; Assay-ID: C\_\_\_1932439\_10), rs16910631 (*CLEC7A*; Assay-ID: C\_\_33748498\_10), rs2066844 (*NOD2*, SNP8, Assay-ID: C\_\_11717468\_20), rs2066845 (*NOD2*; SNP12, Assay-ID: C\_\_11717466\_20), and rs2066847 (*NOD2*, Assay-ID: SNP13 C\_\_60383785\_10). PCR was carried out in 96-well plates, employing a ViiA 7 sequence detection system (Thermo Fisher Scientific). Thermal cycling conditions were: 95 ℃ for 10 min, followed by 40 cycles of 15 s at 95 ℃/1 min at 60 ℃. After PCR, fluorescence was detected and analyzed using TaqManGenotyper software version 1.3. Alternatively, *NOD2* genotypes were determined by Sanger sequencing as described before[22].

***In vitro studies with peripheral blood mononuclear cells***

In this study, previous data from our laboratory were re-evaluated with respect to the rs1285933 genotype[16]. Briefly, peripheral blood mononuclear cells (PBMC) had been isolated from EDTA venous blood, cultured and treated with lipopolysaccharide (1 µg/mL; Sigma-Aldrich, Deisenhofen, Germany) for 6 h. Afterwards, RNA was isolated, reversely transcribed into cDNA and subjected to real-time PCR employing standard procedures and a ViiA 7 sequence detection system. The following human-specific TaqManTM gene expression assays with fluorescently labeled MGB probes were used to quantify target cDNA levels: Hs04398399\_m1 (*CLEC5A*), Hs01099660\_g1 (*CXCL5*), and Hs99999905\_m1 (*GAPDH*). PCR conditions were as follows: 95 ℃ for 10 min, followed by 40 cycles of 15 s at 95 ℃/1 min at 60 ℃.

***Statistical analysis***

The data were stored and analyzed employing IBM SPSS Statistics 25.0 (International Business Machines Corporation, Armonk, New York, United States). Differences between patients and controls were assessed for distributions (genotype, allele and sex) using the *χ2* test or Fisher’s exact test, and for means using the *t*-test for independent samples (age, gene expression data), respectively. Pairwise statistical interaction between SNPs in a linear model was studied employing ANOVA. The Hardy-Weinberg equilibrium was assessed using the *χ2* test with 1 degree of freedom. False discovery rates were controlled by using the Benjamini-Hochberg correction. Values of *P* < 0.05 were considered statistically significant.

**RESULTS**

SNP genotyping was performed on DNA samples from 175 patients with CD and 157 healthy controls. Both study groups are comparable for distribution of sex (*P* = 0.310), while patients with CD were older than healthy volunteers who served as controls (43.1 ± 14.7 *vs* 25.3 ± 5.7 years; *P* < 0.0001). In the context of this study, this age difference was considered acceptable. For the controls, the distribution of all individual SNP genotypes was in accordance with the Hardy-Weinberg equilibrium.

To study associations of CD with SNP genotypes or allele frequencies, four genetic models (genotype, dominant, recessive, or allelic models) were employed (Table 1). As expected, significant associations with CD were found for SNPs in *NOD2*, specifically rs2066844 (SNP8; genotype *P* = 0.0498, dominant *P* value = 0.0219, allelic *P* value = 0.0368) and rs2066847 (SNP13; allelic *P* value = 0.0474). Intriguingly, the genotype AA of rs1285933 in *CLEC5A* was also potentially associated with the disease (recessive model; *P* = 0.0523). The corresponding odds ratios (ORs) are shown in Table 2. For *NOD2*, the odds of having CD might triple in the presence of the risk allele T (rs2066844: OR = 3.29), and double with allele CC (rs2066847: OR = 2.31). Increased ORs are detectable for *CLEC5A*, too. Genotype AA almost doubles the odds of CD (OR = 1.90). Carrying the risk allele A increases the odds of CD by 39% (OR = 1.39), whereas allele G displays a protective effect (OR = 0.72). We could not detect significant associations between CD and the two SNPs in *CLEC7A* (rs2078178, rs16910631) and also not for rs2066845 (SNP12) in *NOD2* (Table 1). The latter finding might be explained by the rare occurrence of the risk allele C in our cohorts of small size.

We next compared patients with different genotypes of rs1285933 in *CLEC5A* (AA, AG and GG, respectively) regarding their clinical characteristics, employing the following parameters: Age, age at diagnosis, duration of the disease, disease location and behavior according to Montreal classification, Crohn’s disease activity index and Harvey–Bradshaw index, history of surgical treatment and treatment with drugs (including antibodies such as tumor necrosis factor-α inhibitors). There were no statistically significant differences between the three genotypes (data not shown).

To study potential functional effects of the rs1285933 polymorphism, we re-evaluated previously published gene expression data from our laboratory. In these studies, PBMC from CD patients and controls had been employed to measure the mRNA expression of a pre-selected set of genes[16]. Using a combined data set from 16 CD patients and 6 healthy controls, we observed no genotype-dependent differences of *CLEC5A* gene expression (Figure 1A). On the other hand, we found that the genotype GG, compared to AG, was associated with significantly lower mRNA levels of the proinflammatory chemokine *CXCL5* (Figure 1B, please note that ΔCt values and expression levels show an inverse and logarithmic relationship that follows the function 2-(∆Ct)).

Located on different chromosomes, the disease-associate SNP of *CLEC5A* is not correlating with disease-associated SNPs of *NOD2* (data not shown). Furthermore, the pairwise contributions to the disease phenotype of the *CLEC5A* SNP and the other SNPs are independent from each other (Table 3).

**DISCUSSION**

To the best of our knowledge, the results of this study suggest for the first time a potential association of SNP rs1285933 with CD. However, our findings need to be interpreted cautiously since they are based on a relatively small number of patients from a single center.

Given that the SNP is located within the *CLEC5A* gene, our data implicate a PRR beyond *NOD2* into the pathogenesis of the disease. The mechanisms that underlie the effect of the *CLEC5A* polymorphism need to be further elucidated. To this end, reinvestigating data from our past work[16] we can report a *trans* effect of rs1285933 on the expression of the chemokine *CXCL5* in PBMC, but not of *CLEC5A* itself. These data suggest that CLEC5A might be functionally affected, *e.g.*, with respect to its ability of ligand binding or downstream signaling. In accordance with this conclusion, SNP rs1285933 has also been suggested to modulate signaling pathways after interactions between the dengue virus and CLEC5A receptors[20]. Other disease associations of SNP rs1285933 have not been reported yet. In a population of Taiwanese children, neither rs1285933 nor other polymorphisms of *CLEC5A* were associated with susceptibility to Kawasaki disease, coronary artery lesion formation, and intravenous immunoglobulin treatment response[26].

Of note, *CLEC5A* is embedded into an intronic region of another gene, *MGAM*, and the two transcripts are known to correlate[27], so that the effect of SNP rs1285933 is not necessarily exclusively related to the C-type lectin domain family member. Interestingly, decreased maltase activities in the small bowel mucosa are common in children with CD[28], and although this is of course no evidence for a genetic association, the role of *MGAM* in the context of IBD may deserve further attention as well.

We also evaluated possible associations of SNP rs1285933 with different clinical characteristics of our CD patients, including disease location, disease behavior and treatment history, but did not obtain significant results. Given that such effects have been reported for *NOD2* variants[29-32], the studies are nevertheless worth to be continued in larger cohorts of patients. To this end, we conclude that the principal effect of SNP rs1285933 is modulation of CD susceptibility through a different molecular pathway than *NOD2*.

PRRs are key regulators of innate immune responses and inflammatory processes[13,14]. For a prominent member of this family, *NOD2*, a role in the pathogenesis of CD is clearly established[4-6]. Our results suggest an association of a polymorphism in another PRR, rs1285933 in *CLEC5A*, but not of rs2078178 and rs16910631 in *CLEC7A*, with CD. A systematic analysis of PRR functions in the context of CD might reveal novel pathomechanistic insights and help to identify new targets for diagnostic and therapy.

**ARTICLE HIGHLIGHTS**

***Research background***

Crohn’s disease (CD) is characterized by a multifactorial etiology and a significant impact of genetic traits. While *NOD2* mutations represent well established risk factors of CD, the role of other genes is incompletely understood.

***Research motivation***

A better knowledge of the molecular basis of CD is considered as an essential prerequisite for a further improvement of diagnostics and therapy.

***Research objectives***

Previous studies from our laboratory have pointed to a possible link between CD and the expression of pattern recognition receptors of the C-type lectin domain family (specifically, *CLEC5A*) in peripheral blood mononuclear cells (PBMC). This observation prompted us to ask if single nucleotide polymorphisms in the genes *CLEC5A* and *CLEC7A* might be associated with the disease.

***Research methods***

DNA samples from patients with CD and healthy donors were subjected to the analysis of single nucleotide polymorphisms in the genes *CLEC5A*, *CLEC7A* and *NOD2*. For studies on gene expression, PBMC from subgroups of both cohorts were employed. Molecular findings were correlated with clinical characteristics of the patients.

***Research results***

For genotype AA of rs1285933 in *CLEC5A*, a potential association with CD and an increased odds ratio were detected. As expected, risk variants of *NOD2* were associated with an increased occurrence of CD as well. Polymorphisms of rs1285933 correlated with *CXCL5* gene expression but had no effect on *CLEC5A* expression in PBMC.

***Research conclusions***

SNP rs1285933 in *CLEC5A* may represent a novel genetic association of CD. The finding, however, needs to be reproduced in multicenter studies with larger numbers of CD patients.

***Research perspectives***

Pattern recognition receptors of the C-type lectin domain family deserve further attention regarding their potential role in the pathogenesis of CD and their relevance as diagnostic markers and therapeutic targets.

**ACKNOWLEDGMENTS**

We thank Mrs. Katja Bergmann for expert technical assistance.

**REFERENCES**

1 **Abraham C**, Cho JH. Inflammatory bowel disease. *N Engl J Med* 2009; **361**: 2066-2078 [PMID: 19923578 DOI: 10.1056/NEJMra0804647]

2 **Baumgart DC**, Sandborn WJ. Crohn's disease. *Lancet* 2012; **380**: 1590-1605 [PMID: 22914295 DOI: 10.1016/S0140-6736(12)60026-9]

3 **Mayer L**. Evolving paradigms in the pathogenesis of IBD. *J Gastroenterol* 2010; **45**: 9-16 [PMID: 19960355 DOI: 10.1007/s00535-009-0138-3]

4 **Naser SA**, Arce M, Khaja A, Fernandez M, Naser N, Elwasila S, Thanigachalam S. Role of ATG16L, NOD2 and IL23R in Crohn's disease pathogenesis. *World J Gastroenterol* 2012; **18**: 412-424 [PMID: 22346247 DOI: 10.3748/wjg.v18.i5.412]

5 **Hugot JP**, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 2001; **411**: 599-603 [PMID: 11385576 DOI: 10.1038/35079107]

6 **Ogura Y**, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 2001; **411**: 603-606 [PMID: 11385577 DOI: 10.1038/35079114]

7 **Natsuka M**, Uehara A, Yang S, Echigo S, Takada H. A polymer-type water-soluble peptidoglycan exhibited both Toll-like receptor 2- and NOD2-agonistic activities, resulting in synergistic activation of human monocytic cells. *Innate Immun* 2008; **14**: 298-308 [PMID: 18809654 DOI: 10.1177/1753425908096518]

8 **Iyer JK**, Coggeshall KM. Cutting edge: primary innate immune cells respond efficiently to polymeric peptidoglycan, but not to peptidoglycan monomers. *J Immunol* 2011; **186**: 3841-3845 [PMID: 21357534 DOI: 10.4049/jimmunol.1004058]

9 **Girardin SE**, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. *J Biol Chem* 2003; **278**: 8869-8872 [PMID: 12527755 DOI: 10.1074/jbc.C200651200]

10 **Inohara N**, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nuñez G. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. *J Biol Chem* 2003; **278**: 5509-5512 [PMID: 12514169 DOI: 10.1074/jbc.C200673200]

11 **Strober W**, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. *Nat Rev Immunol* 2006; **6**: 9-20 [PMID: 16493424 DOI: 10.1038/nri1747]

12 **Zelensky AN**, Gready JE. The C-type lectin-like domain superfamily. *FEBS J* 2005; **272**: 6179-6217 [PMID: 16336259 DOI: 10.1111/j.1742-4658.2005.05031.x]

13 **Hardison SE**, Brown GD. C-type lectin receptors orchestrate antifungal immunity. *Nat Immunol* 2012; **13**: 817-822 [PMID: 22910394 DOI: 10.1038/ni.2369]

14 **Hoving JC**, Wilson GJ, Brown GD. Signalling C-type lectin receptors, microbial recognition and immunity. *Cell Microbiol* 2014; **16**: 185-194 [PMID: 24330199 DOI: 10.1111/cmi.12249]

15 **Iliev ID**, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, Brown J, Becker CA, Fleshner PR, Dubinsky M, Rotter JI, Wang HL, McGovern DP, Brown GD, Underhill DM. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. *Science* 2012; **336**: 1314-1317 [PMID: 22674328 DOI: 10.1126/science.1221789]

16 **Schäffler H**, Rohde M, Rohde S, Huth A, Gittel N, Hollborn H, Koczan D, Glass Ä, Lamprecht G, Jaster R. *NOD2*- and disease-specific gene expression profiles of peripheral blood mononuclear cells from Crohn's disease patients. *World J Gastroenterol* 2018; **24**: 1196-1205 [PMID: 29568200 DOI: 10.3748/wjg.v24.i11.1196]

17 **Cooney R**, Baker J, Brain O, Danis B, Pichulik T, Allan P, Ferguson DJ, Campbell BJ, Jewell D, Simmons A. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. *Nat Med* 2010; **16**: 90-97 [PMID: 19966812 DOI: 10.1038/nm.2069]

18 **Travassos LH**, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhães JG, Yuan L, Soares F, Chea E, Le Bourhis L, Boneca IG, Allaoui A, Jones NL, Nuñez G, Girardin SE, Philpott DJ. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. *Nat Immunol* 2010; **11**: 55-62 [PMID: 19898471 DOI: 10.1038/ni.1823]

19 **Chen ST**, Li FJ, Hsu TY, Liang SM, Yeh YC, Liao WY, Chou TY, Chen NJ, Hsiao M, Yang WB, Hsieh SL. CLEC5A is a critical receptor in innate immunity against Listeria infection. *Nat Commun* 2017; **8**: 299 [PMID: 28824166 DOI: 10.1038/s41467-017-00356-3]

20 **Xavier-Carvalho C**, Cezar RDDS, Freire NM, Vasconcelos CMM, Solorzano VEF, de Toledo-Pinto TG, Fialho LG, do Carmo RF, Vasconcelos LRS, Cordeiro MT, Baptista P, de Azeredo EL, da Cunha RV, de Souza LJ, Pacheco AG, Kubelka CF, Moura PMMF, Moraes MO. Association of rs1285933 single nucleotide polymorphism in CLEC5A gene with dengue severity and its functional effects. *Hum Immunol* 2017; **78**: 649-656 [PMID: 28764923 DOI: 10.1016/j.humimm.2017.07.013]

21 **Chen ST**, Lin YL, Huang MT, Wu MF, Cheng SC, Lei HY, Lee CK, Chiou TW, Wong CH, Hsieh SL. CLEC5A is critical for dengue-virus-induced lethal disease. *Nature* 2008; **453**: 672-676 [PMID: 18496526 DOI: 10.1038/nature07013]

22 **Schäffler H**, Geiss D, Gittel N, Rohde S, Huth A, Glass Ä, Brandhorst G, Jaster R, Lamprecht G. Mutations in the NOD2 gene are associated with a specific phenotype and lower anti-tumor necrosis factor trough levels in Crohn's disease. *J Dig Dis* 2018; **19**: 678-684 [PMID: 30284387 DOI: 10.1111/1751-2980.12677]

23 **Best WR**, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 1976; **70**: 439-444 [PMID: 1248701 DOI: 10.1016/S0016-5085(76)80163-1]

24 **Harvey RF**, Bradshaw JM. A simple index of Crohn's-disease activity. *Lancet* 1980; **1**: 514 [PMID: 6102236 DOI: 10.1016/s0140-6736(80)92767-1]

25 **Silverberg MS**, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol* 2005; **19** Suppl A: 5A-36A [PMID: 16151544 DOI: 10.1155/2005/269076]

26 **Yang YL**, Chang WP, Hsu YW, Chen WC, Yu HR, Liang CD, Tsai YT, Huang YH, Yang KD, Kuo HC, Chang WC. Lack of association between CLEC5A gene single-nucleotide polymorphisms and Kawasaki disease in Taiwanese children. *J Biomed Biotechnol* 2012; **2012**: 398628 [PMID: 22536019 DOI: 10.1155/2012/398628]

27 **Adler P**, Kolde R, Kull M, Tkachenko A, Peterson H, Reimand J, Vilo J. Mining for coexpression across hundreds of datasets using novel rank aggregation and visualization methods. *Genome Biol* 2009; **10**: R139 [PMID: 19961599 DOI: 10.1186/gb-2009-10-12-r139]

28 **Wiecek S**, Wos H, Radziewicz Winnicki I, Komraus M, Grzybowska Chlebowczyk U. Disaccharidase activity in children with inflammatory bowel disease. *Turk J Gastroenterol* 2014; **25**: 185-191 [PMID: 25003680 DOI: 10.5152/tjg.2014.3994]

29 **Büning C**, Genschel J, Bühner S, Krüger S, Kling K, Dignass A, Baier P, Bochow B, Ockenga J, Schmidt HH, Lochs H. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. *Aliment Pharmacol Ther* 2004; **19**: 1073-1078 [PMID: 15142196 DOI: 10.1111/j.1365-2036.2004.01967.x]

30 **Schnitzler F**, Friedrich M, Wolf C, Stallhofer J, Angelberger M, Diegelmann J, Olszak T, Tillack C, Beigel F, Göke B, Glas J, Lohse P, Brand S. The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn's Disease in the Absence of Other NOD2 Mutations. *PLoS One* 2015; **10**: e0116044 [PMID: 26147989 DOI: 10.1371/journal.pone.0116044]

31 **Alvarez-Lobos M**, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S, Lacy AM, Pique JM, Yagüe J, Panés J. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. *Ann Surg* 2005; **242**: 693-700 [PMID: 16244543 DOI: 10.1097/01.sla.0000186173.14696.ea]

32 **Cantó E**, Ricart E, Busquets D, Monfort D, García-Planella E, González D, Balanzó J, Rodriguez-Sanchez JL, Vidal S. Influence of a nucleotide oligomerization domain 1 (NOD1) polymorphism and NOD2 mutant alleles on Crohn's disease phenotype. *World J Gastroenterol* 2007; **13**: 5446-5453 [PMID: 17907287 DOI: 10.3748/wjg.v13.i41.5446]

**Footnotes**

**Institutional review board statement:** The study was approved by the ethic board of the Medical Faculty of the University of Rostock (A 2017-0137). Written informed consent was obtained from each participant prior to enrollment.

**Conflict-of-interest statement:** The authors declare that there is no conflict of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** February 4, 2020

**First decision:** March 21, 2020

**Article in press:** April 29, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Germany

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Mach TH **S-Editor:** Tang JZ **L-Editor:** A **E-Editor:** Zhang YL

**Figure Legends**



**Figure 1 Effects of the rs1285933 genotype on *CLEC5A* and *CXCL5* gene expression.** Peripheral blood mononuclear cells were isolated from individuals with genotype AA (*n* = 8), GG (*n* = 5), and AG (*n* = 9), cultured and treated with lipopolysaccharide (1 µg/mL) for 6 h. Subsequently, the mRNA expression of the indicated genes and the house-keeping control *GAPDH* was analyzed by real-time PCR. Data are presented as averaged ΔCt values ± standard error of mean. a*P* < 0.05 *vs* genotype GG.

**Table 1** **Genotype and allele frequencies of single nucleotide polymorphisms in the genes *CLEC5A*, *CLEC7A* and *NOD2* in Crohn’s disease patients and controls**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **SNP** | **Genotype** | **Cases****(*n* = 175)** | **Controls****(*n* = 157)** | **Allele1** | **Cases (alleles)** | **Controls (alleles)** | **Genotype *P* value2** | **Dominant *P* value2,3** | **Recessive *P* value2,3** | **Allelic *P* value2** |
| *CLEC5A* | rs1285933 | GG | 35 | 36 | G, *A* | 144, 206 | 155, 159 | 0.1093 (0.0285) | 0.9727 (0.5921) | 0.0523(0.0091) | 0.0900 (0.0352) |
| GA | 74 | 83 |
| AA | 66 | 38 |
| *CLEC7A* | rs2078178 | GG | 104 | 100 | G*, A* | 274, 76 | 251, 63 | 1.0000 (0.5713) | 0.9033 (0.4320) | 0.8344 (0.7618) | 0.9107 (0.6335) |
| AG | 66 | 51 |
| AA | 5 | 6 |
| *CLEC7A* | rs16910631 | CC | 153 | 139 | C, *T* | 327, 23 | 294, 20 | 0.8078 (0.7024) | 0.9056 (0.8662) | 0.9269 (0.6045) | 1.0000 (1.0000) |
| CT | 21 | 16 |
| TT | 1 | 2 |
| *NOD2* | rs2066844(SNP8) | CC | 146 | 148 | C, *T* | 319, 31 | 305, 9 | 0.0498 (0.0065) | 0.0219 (0.0019) | 0.9583 (0.5000) | 0.0368 (0.0016) |
| CT | 27 | 9 |
| TT | 2 | 0 |
| *NOD2* | rs2066845(SNP12) | GG | 163 | 149 | G, *C* | 338, 12 | 306, 8 | 0.8481 (0.6453) | 0.8481 (0.6453) | NA | 0.7874 (0.6505) |
| GC | 12 | 8 |
| CC | 0 | 0 |
| *NOD2* | rs2066847(SNP13) | C-C | 147 | 143 | C, *CC* | 316, 34 | 300, 14 | 0.0923 (0.0321) | 0.1569 (0.0682) | 0.1025 (0.0312) | 0.0474 (0.0103) |
| C-CC | 22 | 14 |
| CC-CC | 6 | 0 |

1Italic: Minor allele according to database https://www.ncbi.nlm.nih.gov/snp/. 2Numbers in brackets refer to the *P* value prior to Benjamini-Hochberg correction (23 tests); significant differences (*P* < 0.05) are indicated in bold. 3Refers to the minor allele. SNP: Single nucleotide polymorphism; NA: Not applicable (due to the absence of CC genotype).

**Table 2** **Odds ratios of genotypes and alleles of single nucleotide polymorphisms in the genes *CLEC5A* and *NOD2***

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Gene** | **SNP** | **Genotype/allele** | **Odds ratio** | **95%CI1** | ***P* value1** |
| *CLEC5A* | rs1285933 | AA | 1.90 | 1.18-3.05 | 0.009 |
| GG | 0.84 | 0.50-1.42 | 0.516 |
| AG | 0.65 | 0.42-1.01 | 0.054 |
| A | 1.39 | 1.03-1.90 | 0.034 |
| G | 0.72 | 0.53-0.97 | 0.034 |
| *NOD2* | rs2066844 (SNP8) | TT | NA |
| CC | 0.31 | 0.14-0.67 | 0.003 |
| CT | 3.00 | 1.36-6.60 | 0.006 |
| T | 3.29 | 1.54-7.03 | 0.002 |
| C | 0.30 | 0.14-0.65 | 0.002 |
| *NOD2* | rs2066847 (SNP13) | CC-CC | NA |
| C-C | 0.51 | 0.26-1.02 | 0.056 |
| C-CC | 1.47 | 0.72-2.98 | 0.287 |
| C | 0.43 | 0.23-0.82 | 0.011 |
| CC | 2.31 | 1.21-4.38 | 0.011 |

1Unadjusted for multiple testing. SNP: Single nucleotide polymorphism; NA: Not applicable (missing in controls); CI: Confidence interval.

**Table 3 Pairwise statistical interaction between single nucleotide polymorphisms in a linear model1**

|  |  |  |  |
| --- | --- | --- | --- |
| **SNP** | ***CLEC5A*** | ***CLEC7A*** | ***NOD2*** |
| **rs1285933** | **rs2078178** | **rs16910631** | **rs2066844** | **rs2066845** | **rs2066847** |
| rs1285933 | NA | 0.6490 | 0. 7409 | 0.5266 | 0.6875 | 0.2813 |
| rs2078178 | 0.6490 | NA | 0.1036 | 0.8573 | 0.4040 | 0.3718 |
| rs16910631 | 0.7409 | 0.1036 | NA | 0.8980 | 0.6698 | 0.9270 |
| rs2066844 | 0.5266 | 0.8573 | 0.8980 | NA | 2.8248e-07 | 0.9664 |
| rs2066845 | 0.6875 | 0.4040 | 0.6698 | 2.8248e-07 | NA | 0.7399 |
| rs2066847 | 0.2813 | 0.3718 | 0.9270 | 0.9664 | 0.7399 | NA |

1Disease—single nucleotide polymorphism (SNP) A + SNP B + SNP A: SNP B. The uncorrected *P* values for the last term of an ANOVA are presented in the table for all 30 interactions. The only significance was for two chromosomally neighboring SNPs within *NOD2*. SNP: Single nucleotide polymorphism; NA: Not applicable.